Lenzing's Margin Gain Wins Plaudits, but Grimsby Exit and Heiligenkreuz Sale Keep the Story Unfinished

Lenzing has earned credit for squeezing more out of every euro of revenue. What it has not yet earned is the benefit of the doubt on growth. That distinction frames the group's nine-month 2026 figures, which landed alongside news that production at the Grimsby site will wind down by the end of 2027 and that the Heiligenkreuz plant's fate remains undecided.

The shares rose 3.3% on the day, having already traded 2.9% higher before the opening bell. Lenzing did not draw an explicit link between the price move and its announcements.

Cost Programme Bites as Sites Prepare to Close

Under its performance programme, Lenzing is targeting additional savings of EUR 120 million against last year's actual figures. By 30 September, employment relationships covering more than 260 full-time equivalents had been legally terminated. The plan also includes the planned shutdown of production at two sites: Heiligenkreuz is scheduled to halt output by the end of the first quarter of 2027, and Grimsby by the end of 2027.

Non-cash write-downs on long-term assets at Heiligenkreuz and Grimsby weighed on the result to the tune of EUR 136.1 million. Earnings before interest and taxes came in at EUR -55.1 million for the first nine months of the year.

Should investors sell immediately? Or is it worth buying Lenzing?

Bottom Line Under Pressure, Cash Flow Positive

The net loss after tax widened to EUR 130.3 million, compared with EUR 105.0 million a year earlier. Revenue slipped to EUR 1,926.3 million from EUR 1,972.0 million in the same period of the prior year. Even so, the company generated positive free cash flow of EUR 24.7 million.

Adjusted EBITDA held almost flat at EUR 353.0 million, essentially matching the prior-year level. The adjusted EBITDA margin improved to 18.3% from 17.9%. In the third quarter alone, that margin reached 17.3%, a gain of 4.0 percentage points over the third quarter of 2025.

The combination is respectable from an investor's standpoint: lower revenue, yet a stable adjusted operating result. It would be too harsh to dismiss the development as stagnation purely because of the sales decline — and equally hasty to read a full operational turnaround into it. The improvement is measured on an adjusted earnings figure, not on evidence of higher revenue or a larger net profit. For the full year 2026, Lenzing expects adjusted EBITDA of between EUR 430 million and EUR 460 million.

Heiligenkreuz Still the Litmus Test

Better margins do not automatically resolve the debate over interest in the Heiligenkreuz plant. According to media reports, the field of around 30 prospective buyers is due to be narrowed in mid-November, with a decision on whether a new owner will continue operations expected by the end of the year.

For valuation purposes, the gap between interest and a secured continuation matters. A pool of suitors opens possibilities but guarantees no deal. Neither a successful sale nor continued operation should be booked as progress already achieved — that would be to pre-empt the outcome.

Lenzing at a turning point? This analysis reveals what investors need to know now.

Two separate tests therefore sit side by side. The earnings figures demonstrate a stronger margin. Heiligenkreuz is about a decision still outstanding. Anyone folding both into a finished success story skips over a material caveat. The operating improvements deserve to be judged on their own merits, not upgraded by a hoped-for end to the sale process.

Progress, Not the All-Clear

The verdict is constructive but bounded: Lenzing has delivered on profitability. A stable adjusted EBITDA despite falling revenue is more than cosmetic. For a broader recovery, however, revenue momentum would need to return alongside the better margin. The positive share-price reaction is understandable on that basis; a sweeping all-clear would go too far. The convincing part of the story today is improved earnings quality. Whether it becomes a lasting growth turnaround is the next test.

Ad

Lenzing Stock: New Analysis - 5 November

Fresh Lenzing information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Lenzing analysis...